What is the recommended treatment for oral candidiasis in an adult?

Treatment of Oral Candidiasis in Adults

For mild oral candidiasis, use clotrimazole troches 10 mg five times daily or miconazole mucoadhesive buccal tablet 50 mg once daily for 7–14 days; for moderate to severe disease, use oral fluconazole 100–200 mg daily for 7–14 days. 1

First-Line Treatment by Disease Severity

Mild Disease

• Clotrimazole troches 10 mg five times daily for 7–14 days is the preferred first-line option (strong recommendation, high-quality evidence) 1, 2
• Miconazole mucoadhesive buccal tablet 50 mg applied once daily to the mucosal surface over the canine fossa for 7–14 days is equally effective 1, 2
• These topical agents are superior to nystatin in terms of efficacy and patient acceptance 2

Moderate to Severe Disease

• Oral fluconazole 100–200 mg daily for 7–14 days is the recommended treatment (strong recommendation, high-quality evidence) 1, 2
• Fluconazole demonstrates better clinical response rates than clotrimazole, particularly in immunocompetent patients 3
• This systemic approach is necessary when topical therapy alone is insufficient 2

Alternative Agents for Mild Disease

Nystatin suspension (100,000 U/mL) 4–6 mL four times daily OR nystatin pastilles (200,000 U each) 1–2 pastilles four times daily for 7–14 days may be used as alternatives (strong recommendation, moderate-quality evidence) 1, 2

When to Consider Nystatin

• Patients who cannot tolerate or afford systemic azole therapy 2
• Very mild disease where topical therapy alone is sufficient 2
• Important caveat: Nystatin is NOT first-line therapy and should not be used for moderate to severe disease or in immunocompromised patients 2

Fluconazole-Refractory Disease

If oral candidiasis fails to respond to fluconazole after 7–14 days:

• Itraconazole solution 200 mg once daily OR posaconazole suspension 400 mg twice daily for 3 days, then 400 mg daily for up to 28 days (strong recommendation, moderate-quality evidence) 1
• Alternative options include voriconazole 200 mg twice daily OR amphotericin B deoxycholate oral suspension 100 mg/mL four times daily 1
• For immunosuppressed patients with refractory disease, itraconazole shows lower relapse rates compared to clotrimazole 3

Severe Refractory Cases

• Intravenous echinocandin (caspofungin 70 mg loading dose, then 50 mg daily; micafungin 100 mg daily; or anidulafungin 200 mg loading dose, then 100 mg daily) OR intravenous amphotericin B deoxycholate 0.3 mg/kg daily (weak recommendation, moderate-quality evidence) 1

Special Populations

Immunocompromised Patients (Including HIV)

• Systemic azole therapy with fluconazole is required; nystatin is not recommended (strong recommendation, high-quality evidence) 2
• Antiretroviral therapy should be optimized in HIV-infected patients 1

Denture-Related Candidiasis

• Adjunctive denture disinfection is mandatory when treating denture-associated oral candidiasis (moderate-quality evidence) 2
• Antifungal therapy alone without addressing denture hygiene will result in treatment failure 2

Chronic Suppressive Therapy

• Chronic suppressive therapy is usually unnecessary 1
• If required for patients with recurrent infection, fluconazole 100 mg three times weekly is recommended (strong recommendation, high-quality evidence) 1
• Nystatin is not recommended for long-term prophylaxis 2

Common Pitfalls to Avoid

• Do not use nystatin for moderate to severe disease—it lacks the efficacy of systemic azoles and will delay appropriate treatment 2
• Do not use topical therapy alone in immunocompromised patients—these patients require systemic antifungal treatment from the outset 2
• Do not prescribe treatment courses shorter than 7 days—inadequate duration leads to relapse 1, 2
• Do not ignore denture hygiene in denture wearers—failure to disinfect dentures will result in reinfection regardless of antifungal choice 2